MYC and breast cancer: To recapitulate mTORi resistance acquisition occurring in breast cancer patients in a more appropriate way, we analyzed mammary tumors isolated from immunocompetent mice that were enrolled into a long-term mTORi intervention, we made use of clinically approved mTOR-targeted therapies, and we engaged in mouse modeling using tumor samples of mouse and human origin to functionally pinpoint MYC as an in vivo driver of mTORi resistance.